LT2276473T - Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas - Google Patents

Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas

Info

Publication number: LT2276473T
Authority: LT; Lithuania
Prior art keywords: carbidopa; levodopa; drug delivery; gastroretentive drug; gastroretentive
Prior art date: 2008-04-18

Application number

LTEP09754186.6T

Other languages

English (en)

Inventor

Nadav Navon

Eytan Moor

David Kirmayer

Elena Kluev

Giora Carni

Original Assignee

Intec Pharma Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-18

Filing date

2009-04-17

Publication date

2017-02-27

2009-04-17 Application filed by Intec Pharma Ltd. filed Critical Intec Pharma Ltd.

2017-02-27 Publication of LT2276473T publication Critical patent/LT2276473T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Botany (AREA)
Zoology (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Inorganic Chemistry (AREA)
Media Introduction/Drainage Providing Device (AREA)
Proteomics, Peptides & Aminoacids (AREA)

LTEP09754186.6T 2008-04-18 2009-04-17 Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas LT2276473T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4626108P	2008-04-18	2008-04-18
US12005108P	2008-12-04	2008-12-04
PCT/IB2009/005691 WO2009144558A1 (en)	2008-04-18	2009-04-17	Carbidopa/lipodopa gastroretentive drug delivery

Publications (1)

Publication Number	Publication Date
LT2276473T true LT2276473T (lt)	2017-02-27

Family

ID=41376643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP09754186.6T LT2276473T (lt)	2008-04-18	2009-04-17	Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas

Country Status (18)

Country	Link
US (6)	US8771730B2 (lt)
EP (2)	EP2276473B1 (lt)
JP (2)	JP2011518148A (lt)
KR (1)	KR101601649B1 (lt)
CN (2)	CN102149369B (lt)
CA (1)	CA2721493C (lt)
CY (1)	CY1118296T1 (lt)
DK (1)	DK2276473T3 (lt)
ES (2)	ES2606395T3 (lt)
HR (1)	HRP20161433T1 (lt)
HU (1)	HUE030958T2 (lt)
IL (2)	IL208708A (lt)
LT (1)	LT2276473T (lt)
PL (1)	PL2276473T3 (lt)
PT (1)	PT2276473T (lt)
SI (1)	SI2276473T1 (lt)
WO (1)	WO2009144558A1 (lt)
ZA (1)	ZA201007797B (lt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2606395T3 (es) *	2008-04-18	2017-03-23	Intec Pharma Ltd.	Administración de fármacos gastrorretentivos para carbidopa/levodopa
AU2009281752B2 (en)	2008-08-15	2016-11-17	Depomed Inc.	Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
WO2012059815A1 (en)	2010-11-01	2012-05-10	Intec Pharma Ltd.	Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US10150792B2 (en) *	2010-11-08	2018-12-11	Synthonics, Inc.	Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
WO2014099056A2 (en)	2012-12-20	2014-06-26	Carnegie Mellon University	Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
CN106535878B (zh)	2014-06-02	2022-11-01	科莱西奥生物科技有限公司	可张开的胃内滞留剂型
US20170266112A1 (en)	2014-06-11	2017-09-21	Massachusetts Institute Of Technology	Residence structures and related methods
CN116370644A (zh)	2014-06-11	2023-07-04	麻省理工学院	驻留结构及相关方法
DE102014119576A1 (de)	2014-12-23	2016-06-23	Ernst-Moritz-Arndt-Universität Greifswald	Pharmazeutische Arzneimittelform zur Applikation auf Schleimhäuten
WO2016123576A1 (en)	2015-01-30	2016-08-04	Lieber Institute For Brain Development	Comt inhibiting methods and compositions
US10792366B2 (en)	2015-02-19	2020-10-06	Carnegie Mellon University	Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
CA3254279A1 (en) *	2015-06-03	2025-03-18	Triastek, Inc.	PHARMACEUTICAL FORMS AND RELATED USES
EP3310341A1 (en)	2015-06-17	2018-04-25	Biogen MA Inc.	Dimethyl fumarate particles and pharmaceutical compositions thereof
WO2016205754A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Compositions and methods for modified nutrient delivery
WO2016205701A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Enteral fast access tract platform system
CN118975972A (zh)	2015-10-23	2024-11-19	林德拉治疗公司	用于治疗剂缓释的胃驻留系统及其使用方法
US9849125B1 (en)	2015-11-03	2017-12-26	Banner Lifie Sciences LLC	Anti-overingestion dosage forms
PL3380471T3 (pl) *	2015-11-25	2021-12-20	Lieber Institute Inc. Dba Lieber Institute For Brain Development	Tetrahydro-8h-pirydo[1,2-a]pirazyn-8-ony jako inhibitory comt do leczenia chorób i zaburzeń neurodegeneracyjnych
WO2017096054A1 (en) *	2015-12-01	2017-06-08	Teva Pharmaceutical Industries, Ltd.	Gastric retentive devices
JP7030052B2 (ja)	2015-12-08	2022-03-04	リンドラセラピューティクス，インコーポレイティド	胃滞留システムのための幾何学的構成
US12109305B2 (en)	2016-05-27	2024-10-08	Lyndra Therapeutics, Inc.	Materials architecture for gastric residence systems
KR102443161B1 (ko)	2016-07-11	2022-09-14	콘테라 파르마 에이/에스	아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템
CA3027700A1 (en)	2016-07-11	2018-01-18	Intec Pharma Ltd.	Oral gastroretentive formulations and uses thereof
EP3518902A4 (en)	2016-09-30	2020-07-08	Lyndra, Inc.	GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
EP3320898A1 (en)	2016-11-11	2018-05-16	ratiopharm GmbH	Dosage form comprising a carrier structure and method for manufacturing the dosage form
US10737079B2 (en)	2016-12-02	2020-08-11	Clexio Biosciences Ltd.	Gastric residence system
AU2018212273B2 (en)	2017-01-26	2023-12-21	Triastek, Inc.	Dosage forms of controlled release at specific gastrointestinal sites
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
WO2018227147A1 (en)	2017-06-09	2018-12-13	Lyndra, Inc.	Gastric residence systems with release rate-modulating films
WO2019111132A1 (en)	2017-12-04	2019-06-13	Clexio Biosciences Ltd.	Long acting gastric residence system
CN116270513A (zh)	2018-01-09	2023-06-23	南京三迭纪医药科技有限公司	一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
US11638678B1 (en)	2018-04-09	2023-05-02	Vibrant Ltd.	Vibrating capsule system and treatment method
US12083303B2 (en)	2019-01-21	2024-09-10	Vibrant Ltd.	Device and method for delivering a flowable ingestible medicament into the gastrointestinal tract of a user
US11510590B1 (en)	2018-05-07	2022-11-29	Vibrant Ltd.	Methods and systems for treating gastrointestinal disorders
US20210361566A1 (en)	2018-06-19	2021-11-25	National University Of Singapore	Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications
KR102844663B1 (ko)	2019-01-03	2025-08-11	바이브런트 리미티드	사용자의 위장관 내로 섭취 가능한 약제를 전달하기 위한 디바이스
GB201901470D0 (en)	2019-02-04	2019-03-27	Vibrant Ltd	Vibrating capsule for gastrointestinal treatment, and method of use thereof
US11147767B2 (en) *	2019-02-25	2021-10-19	Rubicon Research Private Limited	Gastroretentive formulations
WO2020230089A1 (en)	2019-05-14	2020-11-19	Clexio Biosciences Ltd.	Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
AU2020303907A1 (en) *	2019-06-28	2022-02-24	Dynamic Biologics Inc.	Levodopa polymeric conjugates, formulations thereof, and their uses for the treatment of Parkinson's disease
CN113116845B (zh) *	2019-12-31	2024-03-19	广州玻思韬控释药业有限公司	胃滞留片
JP7525935B2 (ja) *	2020-03-02	2024-07-31	クラフトヘルスプライベートリミテッド	持続的薬物放出のための経口剤形の製造方法
US11986449B2 (en) *	2020-12-22	2024-05-21	Amneal Pharmaceuticals Llc	Levodopa dosing regimen
WO2022195476A1 (en)	2021-03-15	2022-09-22	Clexio Biosciences Ltd.	Gastroretentive devices for assessment of intragastric conditions
US12409163B2 (en)	2021-07-30	2025-09-09	Evecxia Therapeutics, Inc.	Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
KR20240039030A (ko)	2021-07-30	2024-03-26	에벡시아 테라퓨틱스 아이엔씨.	5-하이드록시트립토판 위체류성 투여 형태
WO2023064598A1 (en)	2021-10-14	2023-04-20	Evecxia Therapeutics, Inc.	A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2024024865A1 (ja) *	2022-07-28	2024-02-01	大原薬品工業株式会社	レボドパ持続性製剤
CN117599009A (zh) *	2023-11-10	2024-02-27	长沙晶易医药科技股份有限公司	一种卡左双多巴三层片及其制备方法
WO2025240494A1 (en)	2024-05-13	2025-11-20	Lumen Bioscience, Inc.	Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4451260A (en) *	1982-03-26	1984-05-29	Minnesota Mining And Manufacturing Company	Sustained release oral medicinal delivery device
US4767627A (en) *	1985-05-29	1988-08-30	Merck & Co., Inc.	Drug delivery device which can be retained in the stomach for a controlled period of time
JPH03163011A (ja) *	1989-08-31	1991-07-15	Yamanouchi Pharmaceut Co Ltd	胃内滞留デバイス
US6322819B1 (en) *	1998-10-21	2001-11-27	Shire Laboratories, Inc.	Oral pulsed dose drug delivery system
EP1064937A1 (en)	1999-06-28	2001-01-03	Sanofi-Synthelabo	Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en)	2000-08-25	2002-11-26	Neurocrine Biosciences, Inc.	Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en)	1999-11-29	2001-03-19	Yissum Res Dev Co	Gastroretentive controlled release pharmaceutical dosage forms
GB9930578D0 (en) *	1999-12-23	2000-02-16	Smithkline Beecham Plc	Pharmaceutical formulations
DE10004790B4 (de)	2000-02-01	2004-09-09	Lts Lohmann Therapie-Systeme Ag	Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
MXPA03012041A (es)	2001-07-04	2004-03-26	Sun Pharmaceutical Ind Ltd	Sistema de administracion controlada de farmacos de retencion gastrica.
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
EP1523981A1 (en)	2003-10-13	2005-04-20	Wyeth	Extended release formulations of venlafaxine
WO2005044199A2 (en)	2003-11-05	2005-05-19	Santarus, Inc.	Combination of proton pump inhibitor and sleep aid
WO2006026504A2 (en) *	2004-08-27	2006-03-09	Spherics, Inc.	Mucoadhesive oral formulations of high permeability, high solubility drugs
IL166183A0 (en) *	2005-01-06	2006-01-15	Yissum Res Dev Co	Novel diagnostic and imaging techniques of the gi tract
PL2997953T3 (pl)	2006-01-18	2019-07-31	Intec Pharma Ltd.	Przyrząd do podawania środka przyjmowanego doustnie
US20090304768A1 (en)	2006-02-15	2009-12-10	Intec Pharma Ltd	Gastro-Retentive System for the Delivery of Macromolecules
US8765178B2 (en)	2006-07-19	2014-07-01	Watson Laboratories, Inc.	Controlled release formulations and associated methods
EP1970056A1 (en)	2007-03-15	2008-09-17	Polichem S.A.	Time-specific delayed/pulsatile release dosage forms
ES2606395T3 (es) *	2008-04-18	2017-03-23	Intec Pharma Ltd.	Administración de fármacos gastrorretentivos para carbidopa/levodopa
CN101309436B (zh)	2008-07-02	2012-04-18	三一重工股份有限公司	一种无线通信设备匹配认证方法、装置及系统
AU2009281752B2 (en)	2008-08-15	2016-11-17	Depomed Inc.	Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
CN102300463B (zh)	2008-12-04	2015-03-25	英特药业有限公司	扎来普隆(zaleplon)胃滞留药物传递系统
WO2012059815A1 (en)	2010-11-01	2012-05-10	Intec Pharma Ltd.	Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
ES2743906T3 (es) *	2011-05-10	2020-02-21	Antecip Bioventures Ii Llc	Dispositivo polimérico implantable para liberación prolongada de sufentanilo

2009
- 2009-04-17 ES ES09754186.6T patent/ES2606395T3/es active Active
- 2009-04-17 CA CA2721493A patent/CA2721493C/en not_active Expired - Fee Related
- 2009-04-17 PL PL09754186T patent/PL2276473T3/pl unknown
- 2009-04-17 LT LTEP09754186.6T patent/LT2276473T/lt unknown
- 2009-04-17 EP EP09754186.6A patent/EP2276473B1/en active Active
- 2009-04-17 CN CN200980120103.9A patent/CN102149369B/zh not_active Expired - Fee Related
- 2009-04-17 KR KR1020107025481A patent/KR101601649B1/ko not_active Expired - Fee Related
- 2009-04-17 PT PT97541866T patent/PT2276473T/pt unknown
- 2009-04-17 EP EP16184987.2A patent/EP3115043B1/en not_active Not-in-force
- 2009-04-17 US US12/937,955 patent/US8771730B2/en not_active Expired - Fee Related
- 2009-04-17 ES ES16184987T patent/ES2849873T3/es active Active
- 2009-04-17 JP JP2011504573A patent/JP2011518148A/ja active Pending
- 2009-04-17 CN CN201610524573.3A patent/CN106176678A/zh active Pending
- 2009-04-17 WO PCT/IB2009/005691 patent/WO2009144558A1/en not_active Ceased
- 2009-04-17 HR HRP20161433TT patent/HRP20161433T1/hr unknown
- 2009-04-17 SI SI200931553T patent/SI2276473T1/sl unknown
- 2009-04-17 DK DK09754186.6T patent/DK2276473T3/en active
- 2009-04-17 HU HUE09754186A patent/HUE030958T2/en unknown
2010
- 2010-10-14 IL IL208708A patent/IL208708A/en active IP Right Grant
- 2010-11-01 ZA ZA2010/07797A patent/ZA201007797B/en unknown
2014
- 2014-07-02 US US14/322,460 patent/US20150010624A1/en not_active Abandoned
- 2014-07-02 US US14/322,436 patent/US9072663B2/en not_active Expired - Fee Related
2015
- 2015-02-26 JP JP2015036404A patent/JP6062465B2/ja not_active Expired - Fee Related
- 2015-05-18 US US14/715,077 patent/US9259387B2/en not_active Expired - Fee Related
2016
- 2016-01-14 US US14/995,611 patent/US9554991B2/en not_active Expired - Fee Related
- 2016-05-11 IL IL245605A patent/IL245605A0/en unknown
- 2016-12-06 CY CY20161101253T patent/CY1118296T1/el unknown
2017
- 2017-01-11 US US15/403,784 patent/US20170119664A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20161433T1 (hr)	2017-01-27
JP2011518148A (ja)	2011-06-23
DK2276473T3 (en)	2017-01-09
IL208708A0 (en)	2010-12-30
HK1158545A1 (zh)	2012-07-20
CA2721493C (en)	2017-11-28
JP6062465B2 (ja)	2017-01-18
US9072663B2 (en)	2015-07-07
JP2015154934A (ja)	2015-08-27
US8771730B2 (en)	2014-07-08
PL2276473T3 (pl)	2017-03-31
CN102149369A (zh)	2011-08-10
US20110117192A1 (en)	2011-05-19
US20150010624A1 (en)	2015-01-08
CN102149369B (zh)	2016-08-10
EP2276473A4 (en)	2013-11-06
US9554991B2 (en)	2017-01-31
US20170119664A1 (en)	2017-05-04
US20150366832A1 (en)	2015-12-24
CN106176678A (zh)	2016-12-07
CA2721493A1 (en)	2009-12-03
ES2849873T3 (es)	2021-08-23
IL208708A (en)	2016-05-31
SI2276473T1 (sl)	2017-02-28
ZA201007797B (en)	2011-07-27
CY1118296T1 (el)	2017-06-28
US9259387B2 (en)	2016-02-16
HUE030958T2 (en)	2017-06-28
EP2276473B1 (en)	2016-09-14
KR20110015549A (ko)	2011-02-16
EP2276473A1 (en)	2011-01-26
WO2009144558A1 (en)	2009-12-03
PT2276473T (pt)	2016-12-15
EP3115043A1 (en)	2017-01-11
ES2606395T3 (es)	2017-03-23
EP3115043B1 (en)	2020-11-25
KR101601649B1 (ko)	2016-03-09
US20140314842A1 (en)	2014-10-23
IL245605A0 (en)	2016-06-30
US20160199300A1 (en)	2016-07-14

Publication	Publication Date	Title
LT2276473T (lt)	2017-02-27	Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas
ZA201104620B (en)	2012-03-28	Zaleplon gastroretentive drug delivery system
IL215608A0 (en)	2011-12-29	Drug delivery composition
ZA200903854B (en)	2011-02-23	A gastroretentive pharmaceutical dosage form
SG2014007389A (en)	2014-04-28	Posterior segment drug delivery
IL216383A (en)	2016-02-29	Stable pharmaceutical preparations containing arginine, levodopa and carbidopa
PT2307079E (pt)	2015-10-14	Dispositivo de administração de medicamentos
IL237392A0 (en)	2015-04-30	Pharmaceutical combination
IL209697A0 (en)	2011-02-28	Dermal delivery
IL228817A0 (en)	2013-12-31	Pharmaceutical compounds
IL213577A0 (en)	2011-07-31	Drug delivery device
IL208387A0 (en)	2010-12-30	Pharmaceutical composition
EP2328511A4 (en)	2014-06-04	ACTIVE RELEASE IMPLANTS
HU0800591D0 (en)	2008-11-28	Stable pharmaceutical combination
GB0803054D0 (en)	2008-03-26	Medicament
IL208953A0 (en)	2011-01-31	Pharmaceutical combination
ZA201006224B (en)	2011-11-30	Pharmaceutical composition
GB2464200B (en)	2013-05-08	Pharmaceutical composition
GB0817969D0 (en)	2008-11-05	Pharmaceutical composition
HU0800414D0 (en)	2008-08-28	Pharmaceutical combination
IL212005A0 (en)	2011-06-30	Novel gastroretentive delivery system
EP2236135A4 (en)	2012-05-02	STABLE PHARMACEUTICAL COMPOSITION
PL385631A1 (pl)	2010-01-18	Pompa perystaltyczna
GB0814986D0 (en)	2008-09-24	Peptide for il10 production
GB0803395D0 (en)	2008-04-02	Medicament